BOOST cells

Phase 2Biologic

KKarolinska Institutet

BOOST cells is one of 7 biologic programs targeting Bone. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BoneActive, not recruiting

BonePhase 2

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Bone

#DrugCompanyPhaseTrials

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 2

BOOST cells

KKarolinska Institutet

Phase 2

1 3

Bone Marrow Aspirate Concentrate

MMassachusetts General Hospital

Preclinical

2 4

Platelet-Rich Fibrin (PRF)

FFederal University of São Paulo

Preclinical

1 5

Vertebral Bone Marrow Clot

IIstituto Ortopedico Rizzoli

Preclinical

1 6

Puregen Osteoprogenitor Cell Allograft

AAlphatec Spine, Inc.

Preclinical

1 7

Elelyso

SShaare Zedek Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1/2Active, not recruiting

Bone

NCT03706482

Clinical

Trials by Indication[1]

Stem Cell Transplantation1 trial

Boost to Brittle Bones - Stem Cell Transplantation for Treatment of Brittle Bones

Unknown status·—·Phase 1/2·NCT04623606·15 enrolled

Bone1 trial

Boost Brittle Bones Before Birth

Active, not recruiting·KKarolinska Institutet·Phase 1/2·NCT03706482·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BOOST cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BOOST cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BOOST cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Karolinska Institutet company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: KKarolinska Institutet

BOOST cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Stem Cell Transplantation1 trial

Bone1 trial

References

Drug Info

Quick Facts

Related News